Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Fallet

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Bulletin Du Cancer|November 25, 2015
[Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer]Etienne Giroux Leprieur, Vincent Fallet, Marie Wislez
La Revue Du Praticien|March 19, 2021
[Risk factors and prevention of lung cancer]Anne-Marie Ruppert, Fatima Amrioui, Vincent Fallet
Respiratory Medicine and Research|May 3, 2022
Invited editorial: Q and A on hereditary lung cancerPatrick R Benusiglio, Vincent Fallet, Jacques Cadranel
La Revue Du Praticien|March 19, 2021
[Impact for smoking cessation in lung cancer patients]Anne-Marie Ruppert, Fatima Amrioui, Vincent Fallet
Bulletin Du Cancer|January 1, 2019
Xavier Mignard, Nouha Chaabane, Vincent Fallet, et al.
European Journal of Human Genetics : EJHG|September 27, 2023
Emerging cancer risks in BRCA2 pathogenic germline variant carriersPatrick R Benusiglio, Antoine Dardenne, Vincent Fallet, et al.
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectivesEtienne Giroux-Leprieur, Vincent Fallet, Jacques Cadranel, et al.
Bulletin Du Cancer|June 21, 2012
[Management of crizotinib, a new individualized treatment]Vincent Fallet, Cécile Toper, Martine Antoine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2022
Do Female <i>BRCA2</i> Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?Vincent Fallet, Mateo Sanchis-Borja, Patrick R Benusiglio, et al.
Respiratory Medicine and Research|June 11, 2023
PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitorsJulie Lasvergnas, Vincent Fallet, Boris Duchemann, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|November 25, 2015
[Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer]Etienne Giroux Leprieur, Vincent Fallet, Marie Wislez
La Revue Du Praticien|March 19, 2021
[Risk factors and prevention of lung cancer]Anne-Marie Ruppert, Fatima Amrioui, Vincent Fallet
Respiratory Medicine and Research|May 3, 2022
Invited editorial: Q and A on hereditary lung cancerPatrick R Benusiglio, Vincent Fallet, Jacques Cadranel
La Revue Du Praticien|March 19, 2021
[Impact for smoking cessation in lung cancer patients]Anne-Marie Ruppert, Fatima Amrioui, Vincent Fallet
Bulletin Du Cancer|January 1, 2019
Xavier Mignard, Nouha Chaabane, Vincent Fallet, et al.
European Journal of Human Genetics : EJHG|September 27, 2023
Emerging cancer risks in BRCA2 pathogenic germline variant carriersPatrick R Benusiglio, Antoine Dardenne, Vincent Fallet, et al.
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectivesEtienne Giroux-Leprieur, Vincent Fallet, Jacques Cadranel, et al.
Bulletin Du Cancer|June 21, 2012
[Management of crizotinib, a new individualized treatment]Vincent Fallet, Cécile Toper, Martine Antoine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2022
Do Female <i>BRCA2</i> Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?Vincent Fallet, Mateo Sanchis-Borja, Patrick R Benusiglio, et al.
Respiratory Medicine and Research|June 11, 2023
PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitorsJulie Lasvergnas, Vincent Fallet, Boris Duchemann, et al.
Pageof 6